Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study
PLOS One · 2026
DOI: 10.1371/journal.pone.0333223 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Yael Eshet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Imaging, Sheba Medical Center, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Crizotinib, Carcinoma, Non-Small-Cell Lung, Protein-Tyrosine Kinases, Anaplastic Lymphoma Kinase. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Progressive arthropathy was anecdotally described in patients exposed to crizotinib, a receptor tyrosine kinases inhibitor (TKI) used to treat anaplastic lymphoma kinase (ALK) or ROS Proto-Oncogene 1 (ROS1) positive non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence of this adverse effect.
Methods
We retrospectively evaluated imaging studies of all patients in our institution receiving TKI for ALK-rearranged or ROS1-positive NSCLC (crizotinib, alectinib, lorlatinib, brigatinib).
Results
Between February 2012 and August 2023, out of a total number of 71 subjects (51% male, 36−88 years old) who received TKI’s for ALK-rearranged/ ROS1 positive NSCLC, 34/71 (47%) were exposed at least once to crizotinib treatment, while the other 37/71 (53%) patients received other TKI’s. Significantly higher incidence (p = 0.02) of irreversible, progressive arthropathy in one or more joints was detected in 18% (6/34, 95% CI: 0.1–0.26) of crizotinib-treated patients, up to 6 years after treatment initiation. Imaging findings included synovial proliferation and progressive arthropathy in hip and shoulder joints, and vertebral endplate destruction.
Conclusion
We found progressive arthropathy, mostly painless, in one or more joints or intervertebral spaces of patients receiving crizotinib for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Imaging, Sheba Medical Center, Ramat Gan, Israel.
- Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel.
- Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel.
ORCID-Profile: Yael Eshet
Zitieren
APA
Eshet, Y., Domachevsky, L., Tau, N., Founshtein, G. P., Eifer, M., Bar, J., & Eshed, I. (2026). Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study. PLOS One. https://doi.org/10.1371/journal.pone.0333223
Vancouver
Eshet Y, Domachevsky L, Tau N, Founshtein GP, Eifer M, Bar J, et al. Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study. PLOS One. 2026. doi:10.1371/journal.pone.0333223
BibTeX
@article{Eshet2026,
author = {Eshet, Yael and Domachevsky, Liran and Tau, Noam and Founshtein, Gregory Peters and Eifer, Michal and Bar, Jair and Eshed, Iris},
title = {Rapidly progressive arthropathy identified on imaging of patients treated with Crizotinib for ALK-rearranged/ROS1-positive non small cell lung cancer: A retrospective single-center study},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0333223}
}
EUVIMED